Biomarkers in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1. alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity 2. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity. 3. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L 4. the prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Written informed consent
• Age ≥ 18 years
• NT-proBNP sample taken by primary care physician as part of routine care for suspected heart failure
Locations
Other Locations
United Kingdom
Glasgow Royal Infirmary
RECRUITING
Glasgow
New Victoria Hospital
RECRUITING
Glasgow
Queen Elizabeth University Hospital
RECRUITING
Glasgow
Contact Information
Primary
Ross Campbell, MBChB
ross.campbell@glasgow.ac.uk
01413302418
Backup
Mark Petrie, MBChB
mark.petrie@glasgow.ac.uk
0141 330 2427
Time Frame
Start Date: 2023-02-02
Estimated Completion Date: 2026-09-29
Participants
Target number of participants: 1028
Treatments
Patients with NTproBNP<125ng/L and clinical suspicion of heart failure in primary care
Expected recruitment of 400 patients (50-60% expected prevalence of obesity, according to population study)
Patients with NTproBNP125-399ng/L and clinical suspicion of heart failure in primary care
Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
Patients with NTproBNP≥400ng/L and clinical suspicion of heart failure in primary care
Expected recruitment of 400 patients (50% expected prevalence of obesity, according to population study)
Related Therapeutic Areas
Sponsors
Collaborators: Roche Diagnostics GmbH, University of Glasgow
Leads: NHS Greater Glasgow and Clyde